Neurofilament light chain (NfL) — a protein that gets released when nerve cells are damaged — is found at high levels in the blood and cerebrospinal fluid (CSF) of people with multiple sclerosis (MS), suggesting its potential as a biomarker of the disease, a study has found. CSF is…
neurofilament light chain
Elevated blood levels of neurofilament light chain (NfL), an established biomarker of nerve damage, are associated with a higher risk of near-term disability worsening in people with multiple sclerosis (MS), according to a large study. Findings imply that there’s usually a window of time — about a year or…
Increased activation of microglia, the resident immune cells in the brain that contribute to chronic inflammation in multiple sclerosis (MS), is significantly associated with higher levels of neurofilament light chain (NfL) protein, indicating more nerve damage, a study found. Researchers particularly identified strong links between…
Treatment with the experimental oral therapy ibudilast (MN-166) does not significantly improve quality-of-life measures compared with a placebo among people with progressive forms of multiple sclerosis (MS), according to new data from a Phase 2 clinical trial. Analyses from the trial suggest that a marker of nerve damage…
Quanterix Corporation‘s laboratory test designed to measure blood levels of neurofilament light chain (NfL) has been validated by the Clinical Laboratory Improvement Amendments (CLIA), an arm of the U.S. Food and Drug Administration (FDA) that regulates laboratory testing. The company now is planning to launch its laboratory developed test,…
Switching from a standard monthly course of Tysabri (natalizumab) to an extended-interval dosing administered every six weeks does not seem to increase neuronal damage in people with multiple sclerosis (MS), a study found. While individual blood levels of neurofilament light chain (NfL), a biomarker of nerve damage, did…
Taking the pregnancy hormone estriol in combination with Copaxone (glatiramer acetate) significantly reduced the blood levels of neurofilament light chain (NfL) — a marker of nerve damage — in women with relapsing-remitting multiple sclerosis (RRMS), clinical trial data show. These lower NfL levels were significantly associated with a…
PoNS Device for MS-associated Gait Problems Now Available in US One clinical trial showed that MS patients who used the portable neuromodulation stimulator (PoNS) device as part of an exercise program had greater improvements in gait than those using only the exercise program. A second trial showed that those…
Quanterix’s ultra-sensitive blood test that measures a biomarker of nerve damage in people with multiple sclerosis (MS) has been granted a breakthrough device designation by U.S. regulators. It is thought that the test, which employs the company’s Simoa technology, can accurately predict the risk of disease activity in…
Serum levels of neurofilament light chain (NfL) — proteins found in nerve cell projections — can help in the prediction of disease progression among people with relapsing forms of multiple sclerosis (MS), according to an analysis of data from two large Phase 3 trials. The researchers said that NfL…
Simoa, a technology that detects relevant molecules in samples with up to 1,000 times greater sensitivity than conventional methods, has helped to advance research into a blood biomarker expected to predict future disease activity in multiple sclerosis (MS) patients. Specifically, Quanterix‘s ultra-sensitive technology allowed an international team…
Administering the stem cell therapy NG-01 — designed to have neuroprotective and neuro-regenerative properties — directly into the spinal canal can significantly reduce the levels of neurofilament light chain (NfL), a neuronal damage biomarker, in people with active, progressive forms of multiple sclerosis (MS). These are the new…
Measuring levels of the neurofilament light chain (NfL) protein in blood may be a way to “quantify” relapse severity and predict future disability in people with relapsing-remitting multiple sclerosis (RRMS). “Higher [blood] NfL levels during periods of active inflammation predicted more [brain] atrophy,” researchers wrote in an abstract titled…
#ACTRIMS2022 – Immune System ‘Reset’ by Stem Cell Transplant At the University of Ottawa, autologous hematopoietic stem cell transplantation (aHSCT) has been used to treat people with aggressive MS since the early 2000s, MS News Today‘s Marisa Wexler reports. This study, which reviewed 71 patients during that period, reports…
Levels of a protein called neurofilament light chain (NfL) in the blood can be used to predict the risk of future disease activity in people with multiple sclerosis (MS), according to a new study. The results also suggest that changes in NfL levels could be used to deduce the extent…
Infection with the common Epstein-Barr virus (EBV) increases the risk of developing multiple sclerosis (MS) by 32 times — the strongest link yet — according to a study looking at two decades of data from more than 10 million U.S. military members. “The hypothesis that EBV causes MS has been…
Measuring levels of the protein serum neurofilament light chain (NfL) can help to identify people with relapsing-remitting multiple sclerosis (RRMS) at higher risk of relapse-free disability progression or conversion to secondary-progressive disease, according to a study from Germany. The study, “NfL predicts relapse-free progression in a longitudinal…
Treatment with evobrutinib, an experimental therapy for relapsing forms of multiple sclerosis (MS), reduced the size of inflammation-associated brain lesions in a Phase 2 clinical trial, data show. The oral medication was also found to be generally safe and well tolerated, according to an analysis of trial data in…
In people with early-stage multiple sclerosis (MS), the presence of high levels of neurofilament light chain (sNfL) protein in the bloodstream combined with thinning of the retina is a strong indicator of future disease activity, a recent study demonstrates. “Our findings encourage the application of both sNfL and retinal…
Larger declines with treatment in blood levels of neurofilament light chain (NfL), a marker of nerve cell damage, are associated with fewer brain lesions, less brain shrinkage, and lower relapse rates in people with relapsing forms of multiple sclerosis (MS), a study reported. These results, based on a post-hoc analysis…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Among people with secondary progressive multiple sclerosis (SPMS) without active disease, high blood levels of the…
People with primary progressive multiple sclerosis (PPMS) have significantly higher levels of a nerve injury-induced protein, called SERPINA3, in the cerebrospinal fluid (CSF) than do those with relapsing-remitting MS (RRMS) and those without the neurodegenerative disease, a study shows. Of note, the CSF is the liquid that bathes…
CXCL13, an inflammatory biomarker, may be a good marker of likely future disease activity in people with multiple sclerosis (MS), a study suggests. The study, “Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis,” was published in the Multiple Sclerosis Journal – Experimental, Translational and Clinical. Clinicians caring…
Immunic Therapeutics is seeking 60 more adults with relapsing-remitting multiple sclerosis (RRMS) to test a lower dose of IMU-838, its leading oral experimental therapy, in its ongoing Phase 2 EMPhASIS trial. The decision was based on previous trial results showing that both doses tested (30 and 45 mg…
The development of a diagnostic test using neurofilament light chain (NfL) — a biomarker for nerve cell damage — for people with multiple sclerosis (MS) will be part of a collaboration program between Siemens Healthineers and Novartis. The goal of this new collaboration is to design, develop,…
Levels of a protein linked to inflammation and neurodegeneration in multiple sclerosis (MS) — called chitinase 3-like-1 (CHI3L1) — may prove to be a cerebrospinal fluid biomarker of neurologic disability in primary progressive MS (PPMS), a pilot study suggests. Higher CHI3L1 levels at PPMS diagnosis showed a…
High levels of neurofilament light chain (NfL) protein circulating in the blood of patients with multiple sclerosis (MS) at an early stage of the disease are linked to higher disability and faster disease progression, a study has found. According to researchers, these findings suggest that NfL — a…
Higher blood levels of the neurofilament light chain (NfL) protein at diagnosis are predictive of worse disability over time in people with multiple sclerosis (MS), a large population study from Sweden suggests. The study, “Plasma neurofilament light levels are associated with the risk of disability in…
A nerve cell protein found in the blood shows potential as a biomarker of neuroinflammation and future neurodegeneration in the early stages of multiple sclerosis (MS), a study reports. The protein, called serum neurofilament light chain (sNfL), is a known marker of injury to axons (nerve…
Starting treatment with a disease-modifying therapy (DMT) reduces blood levels of neurofilament light chain (NfL) — a potential biomarker of disease progression and activity — to varying degrees depending on the therapy used, according to a large real-world study of patients with relapsing-remitting multiple sclerosis (RRMS). The findings support…